Vadastuximab Reference: HY-P99329 Vadastuximab is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine.
Ordesekimab Reference: HY-P99410 Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD).
Risankizumab Reference: HY-P99248 Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd 50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis.
MAPK signaling antibody panel Reference: ARG30349 MAPK signaling antibody; MAP kinase 9; JNK2BETA; PRKM9; EC 2.7.11.24; c-Jun N-terminal kinase 2; Stress-activated protein kinase 1a; SAPK; Stress-activated protein kinase JNK2; MAPK 9; JNK2; JNK2ALPHA; JNK2A; JNK2B; SAPK1a; JNK-55; Mitogen-activated protein kinase 9; p54a; p54aSAPK; JNK3A; Mitogen-activated protein kinase 10; p54bSAPK; Stress-activated protein kinase 1b; JNK3; c-Jun N-terminal kinase 3; Stress-activated protein kinase JNK3; EC 2.7.11.24; SAPK1b; p493F12; MAP kinase 10; PRKM10; MAPK 10; MAP kinase p49 3F12; CSBP2; PRKM14; MAX-interacting protein 2; SAPK2A; Stress-activated protein kinase 2a; CSBP1; Mxi2; EC 2.7.11.24; CSBP; SAPK2a; RK; CSPB1; MAPK 14; p38; MAP kinase 14; MAP kinase MXI2; Cytokine suppressive anti-inflammatory drug-binding protein; MAP kinase p38 alpha; Mitogen-activated protein kinase p38 alpha; EXIP; CSAID-binding protein; p38ALPHA; PRKM15; Mitogen-activated protein kinase 14 ;MAPK 2; MAPK 1; MAP kinase 2; ERK-2; p41; ERK; MAP kinase 1; PRKM2; PRKM1; EC 2.7.11.24; MAPK2; p40; Extracellular signal-regulated kinase 2; p38; Mitogen-activated protein kinase 2; Mitogen-activated protein kinase 1; ERK2; MAP kinase isoform p42; p42-MAPK; P42MAPK; p41mapk; ERT1
Landogrozumab Reference: HY-P99370 Landogrozumab (LY2495655) is an humanized anti-myostatin monoclonal antibody. Landogrozumab effectively improves muscle volume, hand grip strength and function. Landogrozumab can be used for the research of muscle wasting disease.
Iparomlimab Reference: HY-P99668 Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research.
Tefibazumab Reference: HY-P99571 Tefibazumab is a humanized IgG1κ monoclonal antibody that binds to the surface-expressed adhesion protein clumping factor A. Tefibazumab can be used for the research of serious Staphylococcus aureus infections.